Overall survival (OS) of comparing 3 vs 6 months of adjuvant (adjuv) oxaliplatin-based therapy for patients (pts) with stage III colon cancer (CC): Updated results from the IDEA (International Duration Evaluation of Adjuv chemotherapy) collaboration
- Citation:
- J Clin Oncol vol 38 (15_suppl) 4004
- Meeting Instance:
- ASCO 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Parents:
- None
- Children:
- 3380
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA180888 (SWOG);
- Corr. Author:
- Authors:
- Alberto F. Sobrero Andre Thierry Jeffrey A. Meyerhardt Axel Grothey Timothy Iveson Takayuki Yoshino John Souglakos Jeffrey P. Meyers Roberto Labianca Mark Saunders Dewi Vemerey Takeharu Yamanaka Ioannis Boukovinas Eiji Oki Vassilis Gerogoulias Valter Torri Andrea Harkin Julien Taieb Anthony F. Shields Qian Shi
- Networks:
- CORA, LAPS-MA036, LAPS-MN026
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-80702
- Phases:
- 3
- Keywords: